JP2025509390A5 - - Google Patents

Info

Publication number
JP2025509390A5
JP2025509390A5 JP2024553723A JP2024553723A JP2025509390A5 JP 2025509390 A5 JP2025509390 A5 JP 2025509390A5 JP 2024553723 A JP2024553723 A JP 2024553723A JP 2024553723 A JP2024553723 A JP 2024553723A JP 2025509390 A5 JP2025509390 A5 JP 2025509390A5
Authority
JP
Japan
Prior art keywords
acid
caliprazine
composition according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509390A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2023/050150 external-priority patent/WO2023175598A1/en
Publication of JP2025509390A publication Critical patent/JP2025509390A/ja
Publication of JP2025509390A5 publication Critical patent/JP2025509390A5/ja
Pending legal-status Critical Current

Links

JP2024553723A 2022-03-17 2023-02-14 カリプラジン又はその塩を含むデポシステム Pending JP2025509390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320706P 2022-03-17 2022-03-17
US63/320,706 2022-03-17
PCT/IL2023/050150 WO2023175598A1 (en) 2022-03-17 2023-02-14 Depot systems comprising cariprazine or salts thereof

Publications (2)

Publication Number Publication Date
JP2025509390A JP2025509390A (ja) 2025-04-11
JP2025509390A5 true JP2025509390A5 (cg-RX-API-DMAC7.html) 2026-02-24

Family

ID=88022782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553723A Pending JP2025509390A (ja) 2022-03-17 2023-02-14 カリプラジン又はその塩を含むデポシステム

Country Status (9)

Country Link
US (2) US11931357B2 (cg-RX-API-DMAC7.html)
EP (1) EP4493274A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509390A (cg-RX-API-DMAC7.html)
CN (1) CN119136804A (cg-RX-API-DMAC7.html)
AU (1) AU2023234747A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244202A1 (cg-RX-API-DMAC7.html)
IL (1) IL315074A (cg-RX-API-DMAC7.html)
MX (1) MX2024011063A (cg-RX-API-DMAC7.html)
WO (1) WO2023175598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CA3244202A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd. DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF
US20230372331A1 (en) * 2022-05-18 2023-11-23 Anxo Pharmaceutical Co., Ltd. Pharmaceutical composition
CN119424341A (zh) * 2023-08-02 2025-02-14 珠海市华海康医药科技有限责任公司 一种注射用药物缓释微球及其制备方法
CN117137864A (zh) * 2023-11-01 2023-12-01 山东则正医药技术有限公司 一种卡利拉嗪原位凝胶制剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
ES2653852T3 (es) * 2007-08-03 2018-02-09 Richter Gedeon Nyrt. Composiciones farmacéuticas que contienen ligandos del receptor de dopamina y procedimientos de tratamiento usando ligandos del receptor de dopamina
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
AU2017319728B2 (en) * 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
CN108261394B (zh) 2017-01-04 2022-03-04 广东东阳光药业有限公司 一种盐酸卡利拉嗪注射制剂及其制备方法和用途
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
WO2022003662A1 (en) * 2020-06-29 2022-01-06 Mapi Pharma Ltd. Low burst-release liraglutide depot systems
CA3244202A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd. DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF

Similar Documents

Publication Publication Date Title
KR101944367B1 (ko) 부프레노르핀 운반용 약물남용 억제 점막 부착 장치
JP7751638B2 (ja) ガンマ-ヒドロキシ酪酸誘導体の調節放出組成物
CN103842330B (zh) 抗炎的取代的环丁烯二酮化合物的胆碱盐
KR20140088236A (ko) 경구 투여용 코르티코스테로이드 조성물
CN103976968A (zh) 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法
JP7126260B2 (ja) 治療処置用の口腔粘膜ナノファイバ担体
US11931357B2 (en) Depot systems comprising Cariprazine or salts thereof
US20250073170A1 (en) High concentration formulations of anti-csf1 and anti-csf1r antibodies
EP4378527A2 (en) Transmucosal therapeutic system containing agomelatine
CN110072520A (zh) 新型替比培南匹伏酯速释和调释口服剂型
CN117561082A (zh) 治疗重症抑郁和难治性抑郁的方法
US20220401389A1 (en) Transmucosal therapeutic system containing agomelatine
JP2012111773A (ja) 経口吸収改善用医薬組成物
WO2022115056A1 (en) Sustained release formulation compositions comprising propiverine
TWI897768B (zh) 阿哌沙班膜產品用於治療血栓症之用途
CN112672743A (zh) 肝病瘙痒症状的治疗
EP3796908A1 (en) Controlled release propiverine formulations
TWI918360B (zh) 納洛酮口頰膜製劑及其用途
HK40116297A (en) Depot systems comprising cariprazine or salts thereof
HK40126453A (en) Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022229982A1 (en) Oral formulations of edaravone and method of manufacturing thereof
AU2017251803B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
HK40087326A (en) Modified release compositions of a gamma-hydroxybutyric acid derivative
HK40087326B (en) Modified release compositions of a gamma-hydroxybutyric acid derivative
JP2026503785A (ja) 免疫疾患もしくは障害の予防または治療方法に使用するためのマクロライド